학술논문
Fatty Acid-Binding Protein 4 and Risk of Type 2 Diabetes, Myocardial Infarction, and Stroke: A Prospective Cohort Study
CLINICAL RESEARCH ARTICLE
CLINICAL RESEARCH ARTICLE
Document Type
Clinical report
Author
Source
Journal of Clinical Endocrinology & Metabolism. December 2019, Vol. 104 Issue 12, p5991, 12 p.
Subject
Language
English
ISSN
0021-972X
Abstract
Adipocyte fatty acid-binding protein 4 (FABP4) is an intracellular lipid chaperone member of the cytoplasmatic fatty acid binding protein multigene family (1). Formerly deemed exclusive regulator of lipid transport and [...]
Context: Adipocyte fatty acid-binding protein (FABP4) is expressed in adipose tissue and may impair glucose homeostasis and promote atherosclerotic processes. Objective: We examined the association between serum FABP4 and risk of type 2 diabetes (T2D), myocardial infarction (MI), and stroke. Design: Case-cohort study embedded within a sample of 27,548 participants of the EPIC-Potsdam cohort. Participants and Setting: Arandomly selected subcohort(n = 2194) ofparticipants who were free of cardiovascular disease and T2D at study baseline and 728 incident T2D cases, 206 incident stroke cases, and 185 incident MI cases with an average 8.2 (61.7) years of follow-up. Main Outcome Measures: Incident T2D, MI, and stroke. Results: In a multivariable-adjusted model, the hazard ratios (HRs) in the highest vs lowest quartile of FABP4 were 1.81 (95% CI, 1.21 to 2.70; [P.sub.trend] = 0.01) for T2D, 0.93 (95% CI, 0.55 to 1.55; [P.sub.trend] = 0.68) for MI, and 1.41 (95%CI, 0.80to2.49; [P.sub.trend] = 0.24) for stroke, respectively.Inanalyses stratifiedbysex, no statistically significant differences could be seen for associations between FABP4 and T2D and MI ([P.sub.interaction] by sex = 0.27 and 0.84, respectively), whereas a higher risk of stroke was observed in men (HR: 2.70, 95% CI 1.20 to 6.00; P = 0.04), but not in women (HR: 0.70, 95% CI 0.31 to 1.60; P = 0.53; [P.sub.interaction] = 0.02). Conclusions: These data support the hypothesis that elevated FABP4 levels may contribute to T2D risk. In contrast, our data did not support the hypothesis that circulating FABP4 may be relevant for MI, whereas the observed association with stroke in men may need further evaluation. (J Clin Endocrinol Metab 104: 5991-6002, 2019)
Context: Adipocyte fatty acid-binding protein (FABP4) is expressed in adipose tissue and may impair glucose homeostasis and promote atherosclerotic processes. Objective: We examined the association between serum FABP4 and risk of type 2 diabetes (T2D), myocardial infarction (MI), and stroke. Design: Case-cohort study embedded within a sample of 27,548 participants of the EPIC-Potsdam cohort. Participants and Setting: Arandomly selected subcohort(n = 2194) ofparticipants who were free of cardiovascular disease and T2D at study baseline and 728 incident T2D cases, 206 incident stroke cases, and 185 incident MI cases with an average 8.2 (61.7) years of follow-up. Main Outcome Measures: Incident T2D, MI, and stroke. Results: In a multivariable-adjusted model, the hazard ratios (HRs) in the highest vs lowest quartile of FABP4 were 1.81 (95% CI, 1.21 to 2.70; [P.sub.trend] = 0.01) for T2D, 0.93 (95% CI, 0.55 to 1.55; [P.sub.trend] = 0.68) for MI, and 1.41 (95%CI, 0.80to2.49; [P.sub.trend] = 0.24) for stroke, respectively.Inanalyses stratifiedbysex, no statistically significant differences could be seen for associations between FABP4 and T2D and MI ([P.sub.interaction] by sex = 0.27 and 0.84, respectively), whereas a higher risk of stroke was observed in men (HR: 2.70, 95% CI 1.20 to 6.00; P = 0.04), but not in women (HR: 0.70, 95% CI 0.31 to 1.60; P = 0.53; [P.sub.interaction] = 0.02). Conclusions: These data support the hypothesis that elevated FABP4 levels may contribute to T2D risk. In contrast, our data did not support the hypothesis that circulating FABP4 may be relevant for MI, whereas the observed association with stroke in men may need further evaluation. (J Clin Endocrinol Metab 104: 5991-6002, 2019)